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Obesity and exercise constitute important factors for cardiovascular disease risk, but the long-term eﬀects of diﬀerent exercise
modalities on haemostatic biomarkers are not well elucidated. We investigated the eﬀects of 6 months of active commuting or
leisure-time exercise on measures of ﬁbrin turnover in individuals who are overweight and obese. Ninety younger (20–40 years),
sedentary, healthy women and men who are overweight and obese (BMI: 25–35 kg/m2) were randomised to 6 months of habitual
lifestyle (CON, n � 16), active commuting (BIKE, n � 19), or leisure-time exercise of moderate (MOD, ∼50% VO2peak reserve,
n � 31) or vigorous intensity (VIG, ∼70% VO2peak reserve, n � 24). Fasting blood samples (baseline and 3 and 6 months) were
analysed for cholesterols and triglycerides, thrombin generation, prothrombin fragment 1 + 2, D-dimer, ﬁbrin clot properties, and
ﬁbrinolytic activity. We observed no diﬀerences between CON, BIKE, MOD, and VIG during the intervention and no time eﬀects
for any of the variables measured despite increased VO2peak in all exercise groups. We found no diﬀerence between CON and all
exercise groups combined and no gender-speciﬁc eﬀects of exercise. Our ﬁndings suggest that thrombin generation capacity,
coagulation activation, ﬁbrin clot structure, and lysability are unaﬀected by long-term active commuting and leisure-time exercise
in women and men who are overweight and obese.
1. Introduction
Cardiovascular disease (CVD) has a well-known association
with obesity and physical inactivity, and it is well accepted
that regular exercise reduces the overall risk of CVD [1–4].
Nevertheless, the Look AHEAD trial suggested that an in-
tensive lifestyle intervention through caloric restriction and
increased physical activity does not reduce the rate of car-
diovascular events among adults with type 2 diabetes [5].
However, a recent post hoc analysis of the Look AHEAD
trial revealed a reduced risk of cardiovascular mortality after
increased physical activity or weight reduction [6].
From a public health perspective, exercise is a time-
consuming factor in everyday life. As recently suggested by
Andersen [7] and supported by longitudinal and cross-
sectional data, active commuting may be an easy and eﬀective
way to increase daily activity levels [3, 8–11]. Interestingly,
a meta-analysis by Hamer and Chida [12] found a protective
eﬀect of active commuting on cardiovascular outcomes
(mortality, myocardial infarction, coronary heart disease,
hypertension, and stroke), which was more profound
among women than men. In the CARDIA study, active
commuting was associated with increased cardiorespira-
tory ﬁtness in both women and men and a reduced risk of
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obesity and CVD risk factors in men, although not in
women [13]. However, there is still a lack of long-term
randomised controlled trials investigating whether active
commuting and leisure-time exercise of diﬀerent inten-
sities can reduce the risk of CVD to the same extent.
Randomised controlled trials in healthy individuals
assessing CVD incidence as a primary endpoint are practically
infeasible, but intermediate CVD risk markers can instead be
studied. ,rombosis is a key factor in CVD caused by dis-
turbances in the haemostatic balance [14–18], and numerous
studies have tried to elucidate the eﬀects of exercise on the
haemostatic balance [19]. In a recent study [20], we observed
that daily endurance exercise at vigorous intensity for 3
months in overweight men exerts an eﬀect on blood co-
agulation in the direction of anticoagulation, expressed as
reduced endogenous thrombin potential (ETP). Others
have similarly reported that short-term (<3 months) aer-
obic exercise aﬀects the balance between blood coagulation
and ﬁbrinolysis [21–25], but the results are conﬂicting and
may depend on the duration and intensity of the prescribed
exercise regimens. No studies have investigated the eﬀects
of active commuting on the haemostatic balance.
,erefore, the present randomised controlled study is
aimed at determining the eﬀects of 6 months of active
commuting or leisure-time exercise at moderate or vig-
orous intensity on markers of coagulation activation, ﬁbrin
clot properties, and ﬁbrinolytic activity in women and men
who are overweight and obese (class 1), that is, participants
with a high potential of beneﬁt in terms of CVD prevention.
2. Materials and Methods
2.1. Participants and Study Design. ,e project GO-
ACTIWE (Governing Obesity: Active Commuting To Im-
prove health and Wellbeing in Everyday life, http://go.ku.
dk/) is a randomised controlled trial addressing the health
eﬀects of physical activity in adults who are overweight and
obese (class 1), and the participants and study design have
been described in detail elsewhere [26, 27]. All procedures
performed in this study were in accordance with the ethical
standards of the ethics committee of the Capital Region of
Denmark (H-4-2013-108) and with the Helsinki Declara-
tion. ,e trial is registered at http://clinicaltrial.gov (ID-
code: NCT01962259). Recruitment and data collection took
place between October 2013 and June 2016. Informed consent
(written and oral) was obtained from all participants included
in the study.
In brief, we randomised 130 healthy (blood pressure< 140/90mmHg; fasting blood glucose < 6.1 mmol/l; no
regular use of medication), sedentary (regular exer-
cise < 2 hours/week and active commuting <5 km/day;
VO2peak: women < 40 ml O2/kg/min and men < 45 ml
O2/kg/min), young (20–45 years), nonsmoking, Cauca-
sian women and men who are overweight/obese (class 1)
(BMI 25–35 kg/m2; fat percentage: women ≥ 32% and
men ≥ 25%). Exclusion criteria included abnormal rest-
ing electrocardiogram and parents or siblings with type 2
diabetes, and for women, they include postmenopause,
pregnancy, or planned pregnancy [26, 27].
Participants were stratiﬁed for gender and randomly
allocated in a 1 : 2 : 2 : 2 manner to maintain either their
habitual lifestyle in a control group (CON, n � 18), active
commuting by bike (BIKE, self-selected intensity, n � 35),
moderate-intensity leisure-time endurance exercise (MOD,
50% VO2peak reserve, n � 39), or vigorous-intensity leisure-
time endurance exercise (VIG, 70% VO2peak reserve,
n � 38). Active commuting or leisure-time endurance ex-
ercise was prescribed 5 days/week, and the total weekly
exercise dose prescribed in all three exercise groups was
1600 kcal in women and 2100 kcal in men. ,e intervention
period was 6 months, and the exercise intervention was
monitored with the use of heart rate (HR) monitors in-
dividually adjusted after 6 weeks and 3 months based on
changes in maximal HR, VO2peak, and body weight. Ex-
ercise intensity for MOD and VIG was calculated from the
maximal oxygen uptake reserve method [28]. To avoid
potential carry-over eﬀects and preanalytic disturbances, all
participants were instructed not to exercise one day prior to
testing. To avoid seasonal variation, the number of partic-
ipants was evenly distributed throughout the year. Dietary
intake was ad libitum throughout the intervention, and
participants were advised to maintain their habitual diet
[26, 27]. Self-reported energy intake and macronutrient
intake have been published elsewhere and did not change in
any of the intervention groups [29].
To facilitate exercise adherence, participants in all three
exercise groups were instructed to upload training data every
week and were in frequent contact (E-mail, telephone, and
text messages) with the research staﬀ. Adherence to the
exercise intervention from baseline till 6 months was cal-
culated as exercise-induced energy expenditure (% of the
energy expended during the intervention in proportion to
the prescribed energy expenditure) and exercise intensity
(% of VO2peak reserve in proportion to the prescribed
intensity), respectively. Completers demonstrated an excel-
lent exercise energy expenditure adherence (>90% in BIKE,
MOD, and VIG) and intensity adherence (BIKE: self-selected
intensity of 54%; MOD: 49%; VIG: 66%) to the intervention
from baseline till follow-up, and aerobic capacity (VO2peak)
increased during the intervention in all exercise groups
compared with CON [26].
In total, 90 participants completed the study, and the
participant ﬂow, including the number of completers, rea-
sons for dropouts, and participants available for analysis,
including gender distribution, is displayed in Figure 1. ,e
population characteristics are described in Table 1.
2.2. Blood Sampling. Blood samples were obtained at
baseline and at 3 and 6 months between 8.30 and 9.30 am
after an overnight fast (≥10.5 h) including abstention from
alcohol on the day before testing. Blood samples were
collected with minimal stasis by the BD Vacutainer system
(Becton Dickinson, Plymouth, UK) after 20 minutes of rest
in the supine position. Blood samples were collected in
lithium heparin tubes (BD Ref.: 368884) and trisodium
citrate tubes (0.109M Na3citrate, BD Ref.: 363048). Platelet-
poor plasma was prepared by centrifugation of lithium
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heparin tubes for 10min at 2100 xg (4°C) and citrate tubes for
20min at 2000 xg (20°C) immediately after blood sampling.
Plasma was transferred to 500 µl aliquots and stored at −80°C.
2.3. Blood Analyses. Lithium heparin samples were analysed
in one batch for triglycerides and HDL, LDL, and total
cholesterol concentrations with absorption photometry
(Roche Cobas 8000 c702 module).
Citrated plasma samples were rapidly thawed in a water
bath at 37°C and analysed in one series for each participant.
All technicians were blinded to the study groups. e
calibrated automated thrombogram method was applied to
assess plasma thrombin generation (rombinoscope BV,
Maastricht, Netherlands) [30, 31]. e thrombin generation
was performed bymixing 80 µl plasma with 20 µl uorogenic
substrate-calcium chloride (FluCa) and 20 µl trigger reagent
with a nal concentration of 5 pM tissue factor (TF) and
4 µM phospholipids. Fluorescence was read in a Fluoroskan
Ascent microplate uorometer (Fisher Scientic, Slangerup,
Denmark) with a 390/460 nm lter set.rombin generation
curves were generated with the rombinoscope software
(rombinoscope BV, Maastricht, Netherlands) to display
the lag time, time to peak, peak, start tail, and ETP. Velocity
index was dened as the peak divided by the dierence
between the time to peak and lag time.
A commercial ELISA method (Enzygnost F1 + 2;
Siemens, Marburg, Germany) using mouse monoclonal
Individuals showing interest (n = 1546)
Assessed for eligibility (n = 374)
Invited for baseline testing (n = 188)
Randomised (n = 130; W: 69, M: 61)
Completed per protocol 
(n = 24; W: 12, M: 12) 
Completed per protocol 
(n = 31; W: 14, M: 17) 
Completed per protocol 
(n = 19; W: 11, M: 8) 
Completed per protocol 
(n = 16; W: 7, M: 9) 
Ineligible (n = 186) 
Did not show up for screening (n = 126)
Did not meet inclusion criteria (n = 39)
Declined further participation (n = 21)
(i)
(ii)
(iii)
Ineligible (n = 1172) 
Did not meet inclusion criteria (n = 481)
Declined further participation (n = 382)
Other reasons (n = 309)
(i)
(ii)
(iii)
Allocated to CON 
(n = 18; W: 9, M: 9)
Received allocated treatment
(n = 18) 
(i)
Excluded (n = 58)
Withdrew consent (n = 53)
Weight change from screening >5 kg
(n = 1) 
Fasting plasma glucose >6.1 mmol/L
(n = 2) 
Unable to draw blood (n = 2)
(i)
(ii)
(iii)
(iv)
Allocated to BIKE
(n = 35; W: 19, M: 16)
Received allocated treatment
(n = 33)
Did not receive allocated
treatment (n = 2)
(i)
(ii)
Allocated to MOD
(n = 39; W: 21, M: 18)
Received allocated treatment
(n = 39)
(i)
Allocated to VIG
(n = 38; W: 20, M: 18)
Received allocated treatment
(n = 38)
(i)
Missing at 3 months (n = 1)
(i) Time constraints (n = 1)
Lost to follow-up (n = 1)
Dissatisfaction with group
(n = 1)
(i)
Discontinued intervention but 
completed follow-up test (n = 1)
(i) Dissatisfaction with group
(n = 1)
Lost to follow-up (n = 10)
No contact (n = 1)
Time constraints (n = 4)
Pregnancy (n = 1)
Moved abroad (n = 1)
Personal reasons (n = 1)
Unrelated medical issue
(n = 2)
(i)
(ii)
(iii)
(iv)
(v)
(vi)
Completed 3 months (n = 3)
Time constraints (n = 1)
Job relocation (n = 1)
Unrelated medical issue
(n = 1)
(i)
(ii)
(iii)
Completed 3 months (n = 2)
Time constraints (n = 1)
Personal reasons (n = 1)
(i)
(ii)
Discontinued intervention but 
completed follow-up test (n = 2)
(i) Dissatisfaction with group
(n = 1)
Time constraints (n = 1)(ii)
No contact (n = 1)
Dissatisfaction with group
(n = 3)
(i)
(ii)
Lost to follow-up (n = 4)
(i) Pregnancy (n = 1)
Completed 3 months (n = 1)
(i)
(ii)
(iii)
Discontinued intervention but 
completed follow-up test (n = 7)
Time constraints (n = 4)
Personal reasons (n = 2)
Unrelated medical issue 
(n = 1)
No contact (n = 1)
Time constraints (n = 3)
Personal reasons (n = 1)
Unrelated medical issue 
(n = 1)
(i)
(ii)
(iii)
(iv)
Lost to follow-up (n = 6)
Figure 1: Flow of the progress of GO-ACTIWE.
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antibodies was used to measure concentrations of pro-
thrombin fragment 1 + 2 (F1 + 2) in plasma. Concentrations
of D-dimer were measured by an immunoturbidimetric
method (STA-Liatest D-DI; Diagnostica Stago, Asnie´res-sur-
Seine, France).
Global ﬁbrinolytic activity in plasma was determined by
a ﬁbrin plate assay [32]. ,e ﬁbrinolytic activity was cali-
brated against the 3rd International Standard for recom-
binant t-PA (NIBSC 98/714). ,e ﬁbrin clot properties were
studied using turbidity measurements [33–35]. Brieﬂy, plasma
was mixed with thrombin (ﬁnal concentration 0.11 IU/ml)
and CaCl2, with and without addition of rt-PA, and turbidity
was recorded for 30min as optical density (OD) at 405nm.
,e maximal turbidity increment (Vmax) and ﬁbrin clot lysis
were calculated as previously reported [33]. Next, the ﬁbrin
clot structure was determined by measuring the OD at 405,
540, 608, and 690 nm after an overnight incubation, and the
ﬁber mass-length ratio, ﬁber diameter, and ﬁber mass density
were calculated [33].
2.4. Statistics. To ensure adequate power (>80%), the sample
size was determined for the primary outcome, ETP, based on
results from a previous study [26]. ,e calculations sug-
gested inclusion of 140 participants in total: 40 participants
in each exercise group and 20 in the control group [27]. ,e
present analysis of GO-ACTIWE is an eﬃcacy analysis with
the aim to determine biological eﬀects of long-term exercise,
and data were analysed as observed with a per-protocol
analysis.
Baseline values were compared between the four groups
using one-way analysis of variance (ANOVA), and for the
primary eﬀect variable, completers and noncompleters were
compared using a t-test. To determine diﬀerences between
the four groups and account for the multiple time points in
the study design (baseline and 3 and 6 months), a mixed
between-within subjects ANOVA was performed. If no
signiﬁcant group x time interaction was observed, main ef-
fects of time and between-group eﬀects were reported. ,e
mixed between-within subjects ANOVA was adjusted for
relevant confounders (lipids, ETP, time to peak, peak, lag
time, and start tail were adjusted for baseline values of BMI).
Supplementary analyses were conducted to determine
potential gender-speciﬁc eﬀects of exercise. In these analyses,
all exercise groups (BIKE, MOD, and VIG) were pooled to
enable determination of diﬀerences in exercise eﬀects between
women and men. Also, the combined exercise groups
(n � 74) were compared with the control group to examine
the eﬀects of exercise, irrespective of the type of exercise.
Non-normally distributed data (triglycerides, ETP, lag
time, F1 + 2, D-dimer, and ﬁbrinolytic activity) were loga-
rithmically transformed. Data are presented as mean (95%
CI) or geometric mean (geometric 95% CI). p< 0.05 was
considered signiﬁcant. Data were analysed with IBM SPSS
Statistics 23.0 (IBM Corp., Armonk, NY, USA).
3. Results
Concentrations of lipids at baseline and at 3 and 6 months
are presented in Table 2, and measures of the thrombin
generation test (start tail, time to peak, peak, ETP, lag time,
velocity index, F1 + 2, D-dimer, and ﬁbrinolytic activity) and
measures of the ﬁbrin clot structure (Vmax, clot lysis, ﬁber
mass-length ratio, ﬁber diameter, and ﬁber mass density) are
presented in Tables 3 and 4. ,ere were no diﬀerences
between the groups at baseline for any of the variables
measured. Also, baseline values of the primary eﬀect variable
ETP did not diﬀer between completers (1960 (1885; 2037)
nM·min) and noncompleters (1901 (1803; 2004) nM·min)
(p � 0.375).
We observed no diﬀerences between the four groups
during 6 months of intervention. ,us, there were no sig-
niﬁcant interactions between the group and time, no signif-
icant main eﬀects of time, and no signiﬁcant between-group
eﬀects as presented in Tables 2–4.
,e gender-speciﬁc analysis did not reveal interactions
between gender and time for total cholesterol (p � 0.268),
LDL cholesterol (p � 0.236), HDL cholesterol (p � 0.380),
triglycerides (p � 0.438), ETP (p � 0.246), time to peak
(p � 0.171), start tail (p � 0.349), peak (p � 0.174), lag time
(p � 0.533), velocity index (p � 0.231), F1 + 2 (p � 0.399),
D-dimer (p � 0.891), and ﬁbrinolytic activity (p � 0.396), or
for the measures of the ﬁbrin structureVmax (p � 0.116), clot
lysis (p � 0.563), ﬁber mass-length ratio (p � 0.148), ﬁber
diameter (p � 0.128), and ﬁber mass density (p � 0.714).
Furthermore, there were no main eﬀects of time and no
between-gender eﬀects for any of the variables measured
except that women had higher concentrations of HDL
Table 1: Maximal aerobic capacity and body mass index at baseline and at 3 and 6 months.
CON (n � 16) BIKE (n � 19) MOD (n � 31) VIG (n � 24)
Age (years) 35 (31; 39) 35 (32; 39) 33 (30; 35) 36 (34; 40)
VO2peak (ml/min)
Baseline 2792 (2330; 3253) 2678 (2452; 2905) 2700 (2501; 2900) 2684 (2414; 2954)
3 months 2823 (2377; 3269)a 3023 (2737; 3310)∗# 2884 (2657; 3110)∗ 3025 (2729; 3321)∗#
6 months 2770 (2319; 3220) 2975 (2688; 3262)∗# 2926 (2699; 3154)∗# 3068 (2770; 3366)∗#
BMI (kg/m2)
Baseline 30.2 (28.9; 31.5) 30.4 (28.8; 32.0) 29.2 (28.5; 29.9) 30.1 (29.2; 30.5)
3 months 30.8 (29.3; 32.3) 30.0 (28.4; 31.6)# 29.1 (28.3; 29.9) 29.5 (28.5; 30.5)∗#
6 months 30.9 (29.3; 32.5) 29.8 (28.2; 31.4)# 28.9 (28.1; 29.8) 29.3 (28.1; 30.4)∗#
Data are mean (95% CI). an � 14; #signiﬁcantly diﬀerent from CON (ANCOVA adjusted for baseline values); ∗signiﬁcant within the group change from
baseline (repeated measures ANOVA); subjects’ characteristics were previously reported by Gram et al. [26]; CON, control group; BIKE, active commuting
exercise group; MOD, moderate-intensity leisure-time exercise group; VIG, vigorous-intensity leisure-time exercise group; BMI, body mass index.
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cholesterol (p< 0.0005) and lower concentrations of tri-
glycerides (p< 0.01) than men (data not shown).
When the three exercise groups were combined and
compared with the control group, we observed no in-
teractions between the group and time for total cholesterol
(p � 0.508), LDL cholesterol (p � 0.518), HDL cholesterol
(p � 0.263), triglycerides (p � 0.593), ETP (p � 0.688), time
to peak (p � 0.655), start tail (p � 0.769), peak (p � 0.449),
lag time (p � 0.889), velocity index (p � 0.678), F1 + 2
(p � 0.430), D-dimer (p � 0.611), ﬁbrinolytic activity
(p � 0.977), Vmax (p � 0.340), clot lysis (p � 0.637), ﬁber
mass-length ratio (p � 0.897), ﬁber diameter (p � 0.271),
and ﬁber mass density (p � 0.507). Furthermore, there were
no main eﬀects of time and no between-group eﬀects for any
of the variables measured (data not shown).
4. Discussion
,e major ﬁnding in the present study of women and men
who are overweight and obese was that 6 months of active
commuting or leisure-time endurance exercise at two
diﬀerent intensities had no eﬀects on the thrombin gen-
eration potential, markers of coagulation activation, mea-
sures of ﬁbrin clot properties, and ﬁbrinolytic activity in
plasma. Also, no eﬀects were observed for triglycerides and
cholesterols.
No previous long-term (>3 months) exercise studies
have investigated the eﬀects of active commuting and
leisure-time exercise on markers of the haemostatic balance
in healthy, younger women and men who are overweight
and obese. In the present study, the exercise intervention was
very carefully controlled to ensure correct energy expen-
diture, the frequency of exercise, and exercise intensity. ,is
was achieved by monitoring exercise HR and via frequent
contact between the staﬀ and participants. ,e success of the
exercise intervention is supported by the observed increase
in cardiorespiratory ﬁtness in all exercise groups (Table 1).
Furthermore, preanalytical factors potentially aﬀecting co-
agulation activation in vitrowere meticulously controlled for
during blood sampling and handling.
,e thrombin generation test measures the capacity of
plasma to form thrombin. High levels of ETP have been
associated with thromboembolism and arterial vascular
disease [36, 37]. In a previous study, we observed that ETP
was lowered by daily vigorous-intensity endurance exercise
at high and moderate doses for 3 months among healthy
men who are overweight [20]. ,is was not conﬁrmed in the
present study, where no eﬀects on ETP were observed after
3 and 6 months of active commuting or moderate- or
vigorous-intensity leisure-time exercise 4-5 times/week. To
our knowledge, only Hilberg et al. have previously in-
vestigated the eﬀects of physical training on fasting levels of
ETP in healthy adults, and similar to the present study, they
reported no eﬀects of 12 weeks of vigorous-intensity exercise
on men who are overweight and who exercised with a fre-
quency of 3-4 times/week [24].
In the present study, no eﬀects of active commuting or
leisure-time exercise were observed on F1 + 2, D-dimer,
markers of coagulation activation, and cardiovascular risk
[38]. Hilberg et al. [24] also demonstrated unchanged levels
of F1 + 2 following 12 weeks of vigorous-intensity exercise in
men (40–60 y), whereas Lockard et al. [39] showed a de-
crease in F1 + 2 following 6 months of vigorous-intensity
aerobic exercise (3 sessions/week) in combination with the
American Heart Association diet in men and postmeno-
pausal women (50–75 y). ,e deviating ﬁndings may be
ascribed to the age diﬀerence between the populations and
the diﬀerences in dietary habits. ,us, Lockard et al. [39]
demonstrated that exercise combined with a healthy diet is
an excellent primary prevention remedy in an older
Table 2: Concentrations of blood lipids at baseline and at 3 and 6 months.
CON (n � 16) nb BIKE (n � 19) nb MOD (n � 31) nb VIG (n � 24) p values
Cholesterol (mM) 0.833c, 0.518d, 0.179e
Baseline 4.50 (4.15; 4.86) 14 4.83 (4.43; 5.23) 18 4.60 (4.33; 4.86) 28 5.02 (4.59; 5.44)
3 months 4.50 (4.00; 5.00) 14 4.87 (4.55; 5.18) 18 4.59 (4.30; 4.88) 28 4.93 (4.48; 5.37)
6 months 4.31 (4.02; 4.60) 14 4.86 (4.42; 5.30) 18 4.51 (4.27; 4.75) 28 4.93 (4.49; 5.38)
LDL cholesterol (mM) 0.832c, 0.870d, 0.573e
Baseline 2.83 (2.53; 3.12) 14 3.00 (2.62; 3.39) 18 2.83 (2.57; 3.09) 28 3.03 (2.71; 3.34)
3 months 2.78 (2.39; 3.17) 14 3.10 (2.79; 3.41) 18 2.81 (2.59; 3.03) 28 3.08 (2.73; 3.42)
6 months 2.67 (2.40; 2.94) 14 3.07 (2.68; 3.45) 18 2.84 (2.63; 3.05) 28 2.98 (2.58; 3.38)
HDL cholesterol (mM) 0.621c, 0.428d, 0.359e
Baseline 1.18 (1.03; 1.33) 14 1.23 (1.11; 1.35) 18 1.23 (1.09; 1.38) 28 1.31 (1.12; 1.49)
3 months 1.17 (1.00; 1.33) 14 1.31 (1.15; 1.48) 18 1.27 (1.44; 1.40) 28 1.34 (1.16; 1.51)
6 months 1.12 (1.00; 1.23) 14 1.30 (1.15; 1.45) 18 1.28 (1.14; 1.42) 28 1.32 (1.14; 1.50)
Triglycerides (nM)a 0.143c, 0.244d, 0.848e
Baseline 1.05 (0.79; 1.38) 14 1.15 (0.88; 1.51) 18 1.25 (1.02; 1.54) 28 1.13 (0.80; 1.57)
3 months 1.03 (0.70; 1.52) 14 1.09 (0.87; 1.37) 18 1.23 (0.98; 1.54) 28 1.09 (0.85; 1.41)
6 months 1.09 (0.82; 1.44) 14 1.10 (0.84; 1.44) 18 1.02 (0.85; 1.23) 28 1.19 (0.88; 1.60)
Data are unadjusted mean (95% CI) or ageometric mean (geometric 95% CI); bnumber of samples available for analysis; cp values for interactions between the
group and time; dp values for main eﬀects of time for all groups combined; ep values for between-group eﬀects; CON, control group; BIKE, active commuting
exercise group; MOD, moderate-intensity leisure-time exercise group; VIG, vigorous-intensity leisure-time exercise group; LDL, low-density lipoprotein;
HDL, high-density lipoprotein.
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population at higher risk of developing CVD compared to
the younger and healthier population in our study, where we
solely intervened on exercise behavior. In accordance with
our ﬁndings, results from the Look AHEAD study [40]
showed no changes in D-dimer in individuals with type 2
diabetes and in individuals who are obese after a one-year
randomised trial on intensive lifestyle intervention including
exercise and a low-calorie diet.
Active commuting and leisure-time exercise did also not
aﬀect the haemostatic balance in the direction of ﬁbrinolysis
measured as global ﬁbrinolytic activity and ﬁbrin clot lysis.
Furthermore, ﬁbrin clot formation (Vmax) and ﬁbrin ﬁber
structure (ﬁber mass-length ratio, ﬁber diameter, and ﬁber
mass density) did not diﬀer between the groups and did not
change over time. To our knowledge, our study is the ﬁrst
long-term exercise trial focusing on measures of ﬁbrin clot
properties. Fibrin clots composed of compact networks with
thin ﬁbers are more resistant to lysis and are associated with
CVD [41, 42]. Fibrin clot characteristics can be improved by
smoking cessation, medications (e.g., antidiabetics, co-
agulant therapy, and statins) [41, 42], and oral contraceptives
[35]. We demonstrate, however, that long-term exercise
does not add to the list of modiﬁers of clot formation, ﬁber
properties, and clot lysis.
,e lack of eﬀect on clot lysability is supported by the
results for ﬁbrinolytic activity measured by the ﬁbrin plate
Table 3: Biomarkers of coagulation activation at baseline and at 3 and 6 months.
CON (n � 16) nb BIKE (n � 19) nb MOD (n � 31) nb VIG (n � 24) nb p values
ETP (nM·min)a 0.314
c, 0.413d,
0.555e
Baseline 1985 (1819; 2166) 16 2049 (1803; 2328) 18 1975 (1859; 2097) 31 1883 (1750; 2026) 22
3 months 2000 (1844; 2171) 15 2143 (1957; 2346) 16 1963 (1832; 2103) 29 1970 (1849; 2094) 24
6 months 2078 (1907; 2358) 16 2108 (1884; 2358) 16 1965 (1844; 2094) 31 2008 (1858; 2126) 24
Time to peak (min) 0.882
c, 0.942d,
0.453e
Baseline 6.78 (6.26; 7.33) 16 6.46 (5.78; 7.15) 18 6.36 (5.97; 6.75) 30 6.87 (6.23; 7.51) 23
3 months 6.59 (5.97; 7.21) 15 6.24 (5.70; 6.79) 16 6.34 (5.93; 6.34) 29 6.85 (6.28; 7.44) 24
6 months 6.37 (5.66; 7.05) 16 6.28 (5.67; 6.89) 16 6.26 (5.84; 6.68) 31 6.57 (5.96; 7.19) 24
Start tail (min)a 0.934
c, 0.490d,
0.993e
Baseline 26.7 (25.5; 27.9) 16 26.9 (25.6; 28.2) 18 26.5 (25.7; 27.2) 31 26.6 (25.5; 27.5) 22
3 months 27.0 (26.7; 28.4) 15 27.5 (26.3; 28.6) 16 27.0 (25.9; 28.1) 29 26.8 (25.7; 27.9) 24
6 months 26.9 (25.5; 28.9) 16 27.2 (25.8; 28.6) 16 27.5 (25.8; 21.2) 31 27.1 (25.9; 28.1) 24
Peak (nM) 0.550
c, 0.245d,
0.522e
Baseline 301 (264; 339) 16 309 (263; 354) 18 307 (285; 330) 30 283 (256; 313) 22
3 months 306 (274; 338) 15 327 (288; 365) 16 299 (273; 325) 29 289 (263; 314) 24
6 months 329 (289; 368) 16 321 (276; 367) 16 300 (271; 328) 31 303 (278; 327) 24
Lag time (min)a 0.727
c, 0.845d,
0.799e
Baseline 3.40 (3.11; 3.71) 16 3.17 (2.87; 3.49) 18 3.26 (3.00; 3.53) 30 3.29 (2.91; 3.72) 22
3 months 3.39 (2.85; 3.44) 15 3.13 (2.85; 3.42) 16 3.16 (2.91; 3.45) 29 3.34 (2.98; 3.75) 24
6 months 3.26 (2.97; 3.58) 16 3.15 (2.82; 3.53) 16 3.15 (2.86; 3.27) 31 3.25 (2.92; 3.62) 24
Velocity index (nM/min) 0.398
c, 0.155d,
0.372e
Baseline 99 (82; 116) 16 107 (79; 134) 18 111 (96; 127) 30 91 (74; 106) 22
3 months 106 (89; 122) 15 114 (92; 135) 16 109 (91; 128) 29 91 (76; 105) 24
6 months 112 (86; 138) 16 124 (88; 160) 16 104 (90; 118) 31 103 (88; 117) 24
F1 + 2 (pmol/l)a 0.474
c, 0.611d,
0.758e
Baseline 196 (149; 260) 16 212 (184; 245) 17 212 (184; 245) 30 174 (138; 218) 22
3 months 207 (169; 254) 14 198 (164; 240) 16 198 (164; 240) 30 207 (161; 265) 24
6 months 174 (140; 216) 16 223 (184; 271) 16 223 (184; 271) 30 182 (149; 222) 23
D-dimer (µg/l)a 0.622
c, 0.439d,
0.795e
Baseline 0.26 (0.21; 0.32) 16 0.31 (0.25; 0.39) 18 0.29 (0.25; 0.34) 30 0.26 (0.21; 0.30) 23
3 months 0.27 (0.21; 0.35) 15 0.28 (0.21; 0.34) 16 0.27 (0.23; 0.31) 30 0.30 (0.25; 0.37) 24
6 months 0.23 (0.19; 0.29) 16 0.29 (0.23; 0.32) 18 0.27 (0.23; 0.31) 31 0.25 (0.21; 0.30) 24
Data are unadjusted mean (95% CI) or ageometric mean (geometric 95% CI); bnumber of samples available for analysis; cp values for interactions between the
group and time; dp values for main eﬀects of time for all groups combined; ep values for between-group eﬀects; CON, control group; BIKE, active commuting
exercise group; MOD, moderate-intensity leisure-time exercise group; VIG, vigorous-intensity leisure-time exercise group; BMI, body mass index; ETP,
endogenous thrombin potential; F1 + 2, prothrombin fragment 1 + 2.
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assay. ,e plasma ﬁbrinolytic activity is primarily de-
termined by the active forms of tissue plasminogen activator
(t-PA) and its inhibitor plasminogen activator inhibitor type
1 (PAI-1), and no previous studies have assessed the global
ﬁbrinolytic activity in relation to long-term exercise. Only
a few studies have measured t-PA activity and PAI-1 activity
with either no changes observed after 12 weeks of vigorous-
intensity exercise in moderately overweight men [24] or
favorable eﬀects on t-PA activity (increase) and PAI activity
(reduction) after long-term (6–12 months) vigorous-intensity
exercise 3–5 days/week in older, but not younger, men [43]
and in men with peripheral arterial disease [44]. Also, the
protein concentration of PAI-1 (PAI :Ag) aﬀects the global
ﬁbrinolytic activity, and we have recently demonstrated that
active commuting and leisure-time exercise have no eﬀects on
PAI : Ag in the present study [26], thus supporting the results
for global ﬁbrinolytic activity.
We did not also observe any eﬀects on triglycerides
and HDL, LDL, or total cholesterol levels, except minor
diﬀerences in concentrations between women and men. ,e
lack of eﬀect may imply that the participants were too
healthy at study inclusion to obtain eﬀects on blood lipids
following exercise.
It is unclear why we were unable to reproduce our
previous results on increased exercise and reduced ETP, but
one explanation could be that the exercise frequency was
reduced from 6-7 sessions/week in our previous study [20]
to 4-5 sessions/week in the present study. Acute exercise is
known to activate coagulation and ﬁbrinolytic properties
[22, 24, 45–47], and the ﬁndings of the present study, along
with the ﬁndings by Hilberg et al. [24], may suggest that less-
frequent activation of coagulation through ∼4 exercise
sessions/week for 3 or 6 months does not lower ETP levels in
overweight individuals. We speculate that high-frequency
(daily) acute exercise with coagulation activation might
consume coagulation factors and thereby reduce ETP.,is is
supported by Huskens et al. who reported a reduction in
ETP after acute exercise [48]. In the present study, the
participants were instructed not to exercise one day prior to
testing in order to avoid potential carry-over eﬀects of co-
agulation activation and possibly also on ETP. Exercise
intensity does not explain the deviation since the partici-
pants in the VIG group in the present study exercised at the
same intensity as in our previous study [20].
In the statistical analysis of ETP, we adjusted for BMI
due to a signiﬁcant correlation between these two variables.
Table 4: Measures of the ﬁbrin clot structure and ﬁbrinolytic activity at baseline and at 3 and 6 months.
CON (n � 16) nb BIKE (n � 19) nb MOD (n � 31) nb VIG (n � 24) nb p values
Vmax (OD/min)
0.189c, 0.495d,
0.567e
Baseline 0.80 (0.72; 0.89) 15 0.76 (0.70; 0.83) 15 0.86 (0.77; 0.95) 28 0.76 (0.69; 0.84) 22
3 months 0.80 (0.72; 0.88) 15 0.76 (0.69; 0.83) 15 0.80 (0.72; 0.88) 28 0.75 (0.68; 0.81) 22
6 months 0.83 (0.74; 0.91) 15 0.76 (0.65; 0.87) 15 0.77 (0.69; 0.85) 28 0.77 (0.70; 0.83) 22
Clot lysis (%) 0.714
c, 0.476d,
0.061e
Baseline 38.0 (29.5; 46.4) 15 37.5 (31.2; 43.8) 15 44.4 (39.5; 49.2) 28 38.9 (33.5; 44.3) 22
3 months 36.9 (28.8; 45.1) 15 37.7 (30.5; 44.8) 15 48.1 (42.3; 54.0) 28 39.1 (32.8; 45.3) 22
6 months 36.3 (27.7; 44.8) 15 35.4 (28.0; 42.7) 15 45.2 (40.0; 50.7) 28 39.3 (32.4; 46.2) 22
Fiber mass-length ratio
(×1012Da/cm)
0.292c, 0.501d,
0.788e
Baseline 6.76 (6.18; 7.34) 15 7.05 (6.57; 7.54) 15 7.19 (6.73; 7.64) 28 6.86 (6.35; 7.36) 22
3 months 6.85 (6.46; 7.23) 15 7.04 (6.45; 7.63) 15 6.96 (6.50; 7.43) 28 7.02 (6.42; 7.63) 22
6 months 6.87 (6.18; 7.56) 15 7.26 (6.24; 8.28) 15 6.85 (6.50; 7.21) 28 7.49 (6.80; 8.18) 22
Fiber diameter (µm) 0.117
c, 0.883d,
0.761e
Baseline 0.14 (0.13; 0.15) 15 0.14 (0.13; 0.15) 15 0.14 (0.14; 0.15) 28 0.14 (0.13; 0.15) 22
3 months 0.14 (0.14; 0.15) 15 0.14 (0.13; 0.15) 15 0.14 (0.13; 0.14) 28 0.14 (0.13; 0.15) 22
6 months 0.14 (0.14; 0.15) 15 0.13 (0.12; 0.14) 15 0.14 (0.13; 0.14) 28 0.14 (0.13; 0.15) 22
Fiber mass density
(×1022Da/cm3)
0.476c, 0.414d,
0.466e
Baseline 4.53 (4.20; 4.85) 15 5.01 (4.06; 5.97) 15 4.54 (4.33; 4.74) 28 4.54 (4.31; 4.76) 22
3 months 4.33 (4.14; 4.52) 15 4.47 (4.25; 4.69) 15 4.68 (4.43; 4.92) 28 4.62 (4.40; 4.85) 22
6 months 4.30 (4.06; 4.54) 15 5.28 (4.36; 6.20) 15 4.66 (4.48; 4.85) 28 4.75 (4.30; 5.19) 22
Fibrinolytic activity (IU/ml)a 0.878
c, 0.960d,
0.123e
Baseline 78 (52; 117) 15 113 (73; 175) 15 71 (56; 91) 29 94 (69; 130) 22
3 months 76 (54; 106) 15 115 (81; 163) 15 73 (55; 96) 29 93 (69; 124) 22
6 months 78 (54; 112) 15 94 (64; 137) 15 76 (61; 95) 29 99 (73; 133) 22
Data are unadjusted mean (95% CI) or ageometric mean (geometric 95% CI); bnumber of samples available for analysis; cp values for interactions between the
group and time; dp values for main eﬀects of time for all groups combined; ep values for between-group eﬀects; CON, control group; BIKE, active commuting
exercise group; MOD, moderate-intensity leisure-time exercise group; VIG, vigorous-intensity leisure-time exercise group; OD, optical density.
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It is possible that a greater weight loss is necessary to aﬀect
ETP in the direction of anticoagulation, and participants in
our previous study [20] had greater reductions in BMI than
in the present study. Also, we included both women and
men in the present study, and one could speculate that there
is a gender-speciﬁc response to exercise with respect to the
thrombin generation potential. In terms of eﬀects of exercise
on body weight and composition, several studies have
suggested that men experience greater weight loss, body fat
loss, and increase in fat-free mass compared to women
[10, 49, 50]. Furthermore, 44 women completed the present
study, of which 27 (CON: n � 5; BIKE: n � 8; MOD: n � 10;
and VIG: n � 4) used oral contraceptives throughout the
study. Oral contraceptives are known to have procoagulant
properties [51], but it is uncertain whether oral contra-
ceptives modify the eﬀect of exercise on coagulation acti-
vation. However, the subanalyses in the present study did
not reveal any gender-speciﬁc eﬀects of exercise for any of
the variables measured. ,e study was, however, not pow-
ered to reveal gender-speciﬁc eﬀects [26, 27].
Besides the many reported study strengths, the study also
has limitations. ,e power calculations suggested that 140
participants should be included in order to detect signiﬁcant
eﬀects of exercise on ETP. We managed to randomise 130
participants, and due to a variety of reasons (Figure 1),
dropout rates in BIKE and VIG were higher than the ex-
pected 20%. As a consequence, it cannot be excluded that the
lack of signiﬁcant eﬀects may be due to type II errors, al-
though the same number of participants as in VIG revealed
an eﬀect of vigorous exercise training on ETP in our pre-
vious study of only men [20], and in the present study, there
was not even a trend towards a decrease in ETP. ,e sample
size was, however, large enough to demonstrate an eﬀect on
other markers associated with CVD, that is, an increase in
cardiorespiratory ﬁtness (VO2peak) in all the three exercise
groups compared with CON and a decrease in the in-
ﬂammatory marker C-reactive protein in BIKE and MOD
[26], whereas we observed no eﬀects on the classical blood
lipid risk markers. Furthermore, when the exercise groups
were combined into one large group and compared with the
control group, we also did not observe any diﬀerences be-
tween exercise and control groups.
In conclusion, our study suggests that 6 months of active
commuting and leisure-time exercise at diﬀerent intensities
do not have notable eﬀects on markers of coagulation acti-
vation, ﬁbrin clot structure, and lysability in healthy, younger
women and men who are overweight and obese (class 1).
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